D. Boral Capital Reiterates Buy Rating for CollPlant Biotechnologies (NASDAQ:CLGN)

D. Boral Capital reissued their buy rating on shares of CollPlant Biotechnologies (NASDAQ:CLGN) in a research note issued to investors on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $14.00 target price on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $11.00 target price on shares of CollPlant Biotechnologies in a research note on Friday, November 29th.

CollPlant Biotechnologies Trading Down 1.7 %

Shares of CollPlant Biotechnologies stock opened at $3.69 on Tuesday. The company has a 50 day moving average of $3.89 and a 200-day moving average of $4.33. The company has a market cap of $42.19 million, a PE ratio of -2.39 and a beta of 0.86. CollPlant Biotechnologies has a 1-year low of $3.24 and a 1-year high of $6.75.

CollPlant Biotechnologies (NASDAQ:CLGN) last issued its earnings results on Wednesday, November 27th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). CollPlant Biotechnologies had a negative net margin of 2,680.00% and a negative return on equity of 77.05%. During the same period last year, the company posted ($0.38) earnings per share. Research analysts forecast that CollPlant Biotechnologies will post -1.44 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Benjamin Edwards Inc. acquired a new stake in shares of CollPlant Biotechnologies during the 3rd quarter valued at $112,000. AMH Equity Ltd raised its position in CollPlant Biotechnologies by 17.4% in the fourth quarter. AMH Equity Ltd now owns 116,500 shares of the company’s stock valued at $419,000 after purchasing an additional 17,295 shares during the last quarter. Finally, Villere ST Denis J & Co. LLC raised its position in CollPlant Biotechnologies by 24.4% in the third quarter. Villere ST Denis J & Co. LLC now owns 484,867 shares of the company’s stock valued at $2,407,000 after purchasing an additional 95,000 shares during the last quarter. 21.69% of the stock is currently owned by institutional investors and hedge funds.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.